MedTrace Logo

Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease

NCT04344444 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2022-01-21

No results posted yet for this study

Summary

This study proposes to evaluate clinical outcomes and viral load in COVID-19 infected patients with early moderate and severe disease admitted to the hospital and randomized to one of three arms. Patients will be randomized to supportive care, OR hydroxychloroquine alone, OR hydroxychloroquine and azithromycin.

Conditions

Interventions

DRUG

Hydroxychloroquine

tablets provided as described in Arm B

DRUG

Azithromycin

tablets provided as described in Arm C

Sponsors & Collaborators

  • LCMC Health

    lead OTHER

Principal Investigators

  • Meredith Clement, MD · LSUHSC/UMCNO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-13
Primary Completion
2021-04-10
Completion
2022-01-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04344444 on ClinicalTrials.gov